Evenity (Romosozumab): What to Expect, Week-by-Week First Month

What Romosozumab Actually Does Inside Your Skeleton

Romosozumab binds and inhibits sclerostin, a glycoprotein secreted by osteocytes that normally suppresses the Wnt signaling pathway [1]. Blocking sclerostin simultaneously activates osteoblasts (bone-building cells) and reduces osteoclast activity. No other approved osteoporosis drug does both at once.

The Dual-Action Mechanism in Plain Terms

Think of sclerostin as a brake on bone building. Romosozumab removes that brake. Within days of the first injection, serum procollagen type 1 N-terminal propeptide (P1NP), the primary bone-formation marker, begins rising. At the same time, C-terminal telopeptide of type I collagen (CTX), the standard bone-resorption marker, starts falling [2].

This dual shift is transient by design. By months 9 to 12 of the 12-month course, formation markers return toward baseline while resorption suppression persists. That is why the treatment window is capped at 12 months and why sequential antiresorptive therapy (typically denosumab or a bisphosphonate) is mandatory to protect the new bone laid down during treatment [3].

Why the First Month Sets the Tone

The largest bone-turnover changes occur in the first 4 to 8 weeks. Missing a monthly dose or delaying it significantly reduces cumulative BMD gain. The FRAME trial (N=7,180) showed a +13.3% lumbar spine BMD gain vs. Placebo after 12 consecutive monthly doses [4]. Interrupted dosing was not studied, and the prescribing information advises against gaps exceeding a few weeks when possible.

Week 1: The Injection Day and the 24 Hours That Follow

What Happens at the Clinic

Romosozumab is dispensed as two prefilled syringes, each containing 105 mg/1.17 mL. Both are given at the same visit, injected into the abdomen, upper arm, or thigh. Your provider will separate the two injection sites by at least 2.5 cm (roughly one inch). The injections take under two minutes total [5].

Before the first dose your prescriber should confirm:

• Serum calcium is within the normal range (hypocalcemia is a listed contraindication) [5]
• You have been taking supplemental calcium (at least 1,000 mg daily) and vitamin D (at least 800 IU daily) for several weeks beforehand
• No history of MI or stroke in the past 12 months (FDA black-box contraindication) [5]

Injection-Site Reactions

The most common early adverse events are injection-site reactions. Across both key trials, roughly 18% of participants reported at least one injection-site reaction over the entire 12-month course, compared with about 10% in the placebo arm [4,5]. Reactions are typically mild: brief redness, swelling, or tenderness resolving within 24 to 72 hours. Applying a cool pack for 10 minutes post-injection reduces local discomfort for most patients.

Systemic Symptoms in the First 48 Hours

Unlike the flu-like reaction seen after the first dose of zoledronic acid, romosozumab does not trigger an acute-phase response [6]. The vast majority of patients report no systemic symptoms in week 1. Fatigue and mild muscle ache have been documented in post-marketing experience at rates not significantly above those reported with placebo in controlled data.

Week 2: The Bone-Formation Surge Peaks

Serum P1NP peaks approximately 14 days after the first romosozumab injection. In the phase 3 FRAME trial, P1NP rose by roughly 145% above baseline by the end of week 2 [4]. This is the most dramatic bone-formation marker increase seen with any approved osteoporosis agent, including teriparatide, which raises P1NP by approximately 80 to 100% at its peak.

What You Will (and Will Not) Notice

You will not feel bone building. Patients often ask whether joint stiffness or warmth around the spine or hips signals new bone formation. The answer is no. These would more likely reflect arthralgia, listed as an adverse event occurring in about 10% of romosozumab patients in FRAME [4]. True bone remodeling produces no perceptible sensation.

What your lab work will show: if your provider checks a fasting P1NP or bone-specific alkaline phosphatase at week 2, both should be clearly elevated compared with your pre-treatment baseline. Some clinicians use this response as a proxy for adherence and pharmacological effect.

Arthralgia and Headache

Arthralgia (joint pain) occurred in 10.7% of romosozumab-treated participants vs. 10.2% placebo in FRAME [4]. Headache was reported at comparable rates in both arms. Neither symptom requires dose interruption unless severe. Persistent or worsening joint pain beyond week 2 warrants a call to your provider to rule out concurrent conditions.

Week 3: Resorption Suppression Takes Hold

By week 3, serum CTX has typically fallen 15 to 20% below the patient's pre-treatment baseline [2]. This is less resorption suppression than denosumab or bisphosphonates achieve, which is intentional. Romosozumab's primary value in this window is formation, not resorption blockade.

Hypocalcemia Watch Window

Weeks 2 to 4 represent the period of greatest risk for asymptomatic hypocalcemia, particularly in patients with vitamin D insufficiency (<20 ng/mL) at baseline. The FDA label requires correction of hypocalcemia before starting romosozumab and adequate calcium and vitamin D supplementation throughout [5]. Symptoms to watch for include perioral tingling, hand or foot cramping, and muscle spasms. Any of these should prompt same-day contact with your provider and a serum calcium check.

Osteonecrosis of the Jaw (ONJ): Setting Realistic Expectations

ONJ risk with romosozumab exists but is low. In the FRAME trial, ONJ occurred in 0.0% of the romosozumab arm and 0.0% of the placebo arm over 12 months; cases have emerged in post-marketing data at a rate estimated below 1 in 10,000 treatment courses [5]. Preventive steps include completing any needed dental work before starting therapy and maintaining routine oral hygiene. A dental clearance visit before your first injection is standard practice at most metabolic bone disease centers.

Week 4: Before Your Second Injection

By day 28 to 30, serum P1NP begins declining from its week-2 peak, though it remains above baseline. This is normal pharmacodynamic behavior. The dose given on day 30 (month 2) re-stimulates the P1NP surge, and this cycle repeats across all 12 months.

Cumulative BMD Changes at Month 1

A single injection does not produce radiographically detectable BMD change. DEXA scanning is not recommended at month 1. The prescribing information and American Society for Bone and Mineral Research (ASBMR) guidelines recommend repeat DEXA at 12 months (after completing the full course) and again 12 months after transitioning to antiresorptive therapy [3,7].

The 12-month FRAME data show:

| Site | Romosozumab | Placebo | |------|-------------|---------| | Lumbar spine | +13.3% | 0.0% | | Total hip | +6.9% | -0.1% | | Femoral neck | +5.9% | -0.3% |

Source: Cosman et al., NEJM 2016 [4].

Checklist Before Month 2 Injection

• Confirm you have been taking calcium and vitamin D daily
• Report any new chest pain, shortness of breath, or neurological symptoms immediately (cardiovascular safety signals)
• Schedule the month 2 injection within a 7-day window of the 30-day mark
• Flag any dental pain, jaw swelling, or tooth mobility to your provider before the next injection

The ARCH and FRAME Trials: What the Numbers Mean for Your Care

ARCH Trial (NEJM 2017): Head-to-Head vs. Alendronate

The ARCH trial (N=4,093) randomized postmenopausal women with osteoporosis and a prior vertebral fracture to romosozumab 210 mg monthly for 12 months followed by alendronate, vs. Alendronate alone for 24 months [8]. The sequential romosozumab-to-alendronate arm produced a 48% reduction in new vertebral fractures (6.2% vs. 11.9%, P<0.001) and a 27% reduction in clinical fractures vs. Alendronate alone at 24 months [8].

The ARCH trial also reported a higher rate of serious cardiovascular events (adjudicated MI plus stroke) in the romosozumab arm: 2.5% vs. 1.9% (P=0.07, not statistically significant but the basis for the FDA black-box warning) [8]. This finding directly shaped the contraindication language.

FRAME Trial (NEJM 2016): Placebo-Controlled 12-Month Data

The FRAME trial (N=7,180) showed that romosozumab 210 mg monthly for 12 months reduced new vertebral fractures by 73% vs. Placebo at 12 months (0.5% vs. 1.8%, P<0.001) [4]. Clinical fractures were reduced by 36% (P<0.001) [4]. No significant difference in cardiovascular events was detected vs. Placebo in FRAME, which enrolled a lower-risk cardiovascular population than ARCH.

As the FRAME investigators wrote: "Romosozumab treatment for 12 months in postmenopausal women with osteoporosis significantly reduced the risk of vertebral fracture." [4]

Cardiovascular Safety: The Black-Box Warning Explained

The FDA added a black-box warning to Evenity in April 2019 based on the ARCH cardiovascular imbalance [5,8]. The warning states that romosozumab "may increase the risk of myocardial infarction, stroke, and cardiovascular death" and is contraindicated in patients with a history of MI or stroke within the preceding 12 months [5].

Practical Screening Before Prescribing

Before initiating romosozumab, most endocrinologists and metabolic bone specialists follow a pre-treatment cardiovascular screen:

1. Obtain a detailed history of MI, stroke, TIA, unstable angina, and coronary revascularization.
2. Consider cardiology co-management for patients with multiple cardiovascular risk factors.
3. Review concurrent medications: patients on antiplatelet or anticoagulant therapy require individualized risk-benefit discussion.

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines for postmenopausal osteoporosis recommend romosozumab as a first-line option for patients at very high fracture risk who do not have a recent history of MI or stroke [9].

As the AACE guidelines state: "Romosozumab is an option for patients at very high fracture risk, provided cardiovascular risk factors have been assessed and there is no recent history of MI or stroke." [9]

Who Is the Ideal Candidate for Romosozumab?

The following decision framework synthesizes the AACE 2020 guidelines [9], the ARCH trial eligibility criteria [8], and the FDA prescribing information [5] to help clinicians identify appropriate candidates at the time of treatment initiation.

Strong candidates (all criteria should be met):

• Postmenopausal woman or man age 50 or older with osteoporosis (T-score <-2.5 at lumbar spine, total hip, or femoral neck) OR prior low-trauma vertebral or hip fracture
• FRAX 10-year major osteoporotic fracture risk >20% or hip fracture risk >3% (WHO thresholds) [10]
• No MI or stroke in the past 12 months
• Willing and able to take calcium and vitamin D supplements throughout
• Committed to sequential antiresorptive therapy after completing the 12-month course

Patients who need individualized assessment:

• Prior use of denosumab (rebound resorption risk after denosumab discontinuation is a separate concern; romosozumab after denosumab has limited data)
• History of atypical femoral fractures on bisphosphonate therapy (drug holiday may be appropriate before starting romosozumab)
• Active malignancy or recent radiation to the skeleton
• Chronic kidney disease stage 4 to 5 (romosozumab has not been adequately studied in eGFR <30 mL/min/1.73m²) [5]

Monitoring During the First Month and Beyond

Laboratory Tests

Your provider should check or confirm the following before dose 1 and at intervals throughout:

• Serum calcium and phosphorus (pre-dose and at month 1 if any hypocalcemia symptoms) [5]
• 25-hydroxyvitamin D (correct to >30 ng/mL before starting) [9]
• Renal function panel (CMP) to screen for CKD that could worsen drug-related hypocalcemia
• Optional but informative: fasting P1NP and CTX at baseline and at month 3 to confirm pharmacodynamic response [3]

DEXA Scan Timing

DEXA at baseline before the first injection establishes the reference point for all future comparisons. The next scan is appropriate at 12 months (end of romosozumab course) and again 1 to 2 years after starting the subsequent antiresorptive agent. Scanning earlier than 12 months provides little actionable information because BMD gains accrue progressively across all 12 doses [7].

Transition Planning

The 12-month treatment course is not optional to extend. Romosozumab's FDA approval covers exactly 12 monthly injections. After dose 12, the formation benefit dissipates within months unless bone is protected by an antiresorptive drug. ARCH showed that the fracture-risk reduction advantage persists at 24 months only because patients transitioned to alendronate after romosozumab [8]. Denosumab 60 mg every 6 months or a bisphosphonate are the most commonly selected sequential agents [3,9].

Practical Tips for Month 1 Tolerability

Managing Injection-Site Discomfort

• Remove the prefilled syringes from the refrigerator 30 minutes before injection; room-temperature solution reduces stinging.
• Apply ice for 5 minutes pre-injection to numb the site.
• Rotate injection sites each month among abdomen, upper arm, and thigh.
• Avoid injecting into skin that is red, bruised, or irritated.

Vitamin D and Calcium Timing

Take calcium in divided doses of 500 mg or less to maximize absorption. Calcium carbonate requires food for adequate absorption; calcium citrate does not. Vitamin D3 (cholecalciferol) is preferred over D2 (ergocalciferol) because it raises and sustains serum 25-hydroxyvitamin D levels more effectively [11].

When to Call Your Provider

Contact your prescriber the same day if you experience:

• Chest pain or pressure, or sudden shortness of breath (cardiovascular warning)
• Sudden numbness, weakness, or confusion (stroke warning)
• Tingling around the mouth or in the hands and feet (hypocalcemia)
• Jaw pain, swelling, or a non-healing dental wound (ONJ)
• Thigh or groin pain that is new, dull, and persistent (atypical femoral fracture prodrome)